Immunomedics has released results from two clinical trials of its cancer drug Trodelvy (sacituzumab govitecan-hziy) in which the drug showed more promise in breast cancer and bladder cancer.

In a phase 3 study of the drug in metastatic triple-negative breast cancer, Trodelvy reduced the risk of death by 52 percent and had an overall survival rate of 12.1 months compared to 6.7 months with chemotherapy.

A separate phase 2 study evaluating the drug in heavily pretreated patients with metastatic urothelial cancer found that Trodelvy achieved a 27 percent overall response rate and a 5.9-month median duration of response.

Gilead Sciences is acquiring Trodelvy as part of its $21 billion acquisition of Immunomedics.